SecBot SecBot
8-K ·Filed Apr 29, 2026

GEHC

GE HealthCare Technologies Inc.
BEARISH
Impact 7/10
Horizonweeks Processed6mo ago SEC0001932393-26-000030
8-K Item 2.02: Earnings release
Actionable Insight ▼ Bearish

The lowered profit and cash flow guidance for 2026, driven by persistent inflation and a supplier issue, is a material negative. Monitor upcoming quarters for margin recovery and the impact of price/cost actions. The maintained topline guidance provides some support, but the earnings miss and guidance cut are likely to weigh on the stock near-term.

DirectionBearish
Confidencehigh
Horizonweeks

How the stock moved after the report

BEARISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$59.49
T+0 close · Apr 29, 2026 · via day close
Latest settled
+1.84%
T+60 · $60.58
Vs SPY
−2.27%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 29 $59.49entry
  2. T+1 · 7mo ago +2.28%α +1.25% · $60.84
  3. T+5 · 7mo ago +2.61%α −0.50% · $61.04
  4. T+20 · 6mo ago +7.39%α +1.93% · $63.88
  5. T+60 · 4mo ago +1.84%α −2.27% · $60.58
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

GE HealthCare reported Q1 2026 revenue of $5.13B (+7.4% YoY) and GAAP diluted EPS of $0.85, down from $1.23 YoY. Adjusted EPS was $0.99 vs $1.01 YoY, missing the $1.07 consensus. The company lowered full-year 2026 Adjusted EBIT margin guidance to 15.4%-15.7% (from 15.8%-16.1%), Adjusted EPS guidance to $4.80-$5.00 (from $4.95-$5.15), and Free Cash Flow guidance to ~$1.6B (from ~$1.7B), citing inflation in memory chips, oil, and freight costs plus a PDx supplier issue. The lowered guidance and earnings miss are the primary negative signals.

Key Financial Metrics

EPS
$0.99
est $1.07 · -7.5%
Revenue
$5.1B
est $5.0B · +2.0% · +7.4% YoY
Rating
miss
Guidance
Organic revenue growth 3.0%-4.0%
lowered
Free Cash Flow
$112.0M

Key Facts

  • Q1 2026 revenue $5.13B, up 7.4% YoY; organic revenue growth 2.9%
  • GAAP diluted EPS $0.85 vs $1.23 YoY; Adjusted EPS $0.99 vs $1.01 YoY
  • Net income $389M vs $564M YoY; net income margin 7.6% vs 11.8%
  • Adjusted EBIT margin 13.5% vs 15.0% YoY, down 150 bps
  • Full-year 2026 guidance lowered: Adjusted EBIT margin 15.4%-15.7% (from 15.8%-16.1%), Adjusted EPS $4.80-$5.00 (from $4.95-$5.15), Free Cash Flow ~$1.6B (from ~$1.7B)
  • Organic revenue growth guidance maintained at 3.0%-4.0%
  • Cash from operations $290M; Free Cash Flow $112M
  • Closed Intelerad acquisition for $2.3B; repurchased 1.4M shares for $100M
  • Patient Care Solutions segment revenue declined 6.5% YoY; segment EBIT down 79.8%

Financial Impact

Full-year Adjusted EPS guidance cut by ~$0.15 at midpoint ($4.90 vs prior $5.05), Free Cash Flow guidance cut by $100M to ~$1.6B

revenueepsmarginscashFlowguidance

Risk Factors

  • Inflation in memory chips, oil, and freight costs may persist, further pressuring margins
  • PDx supplier issue, though resolved, may have lingering effects on profitability
  • Integration risk from the $2.3B Intelerad acquisition
  • Tariff impact in 2026, though expected to be lower than 2025, remains uncertain

Market Snapshot

Exchange
Nasdaq
Sector
X-Ray Apparatus & Tubes & Related Irradiation Apparatus
Analyst Consensus
68% bullish (28 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001932393-26-000030
Document: 0001932393-26-000030-index-headers.html0001932393-26-000030
Document: 0001932393-26-000030-index.html0001932393-26-000030
Document: 0001932393-26-000030.txt0001932393-26-000030
8-K Data (Synthetic)0001932393-26-000030

Track record

13 reports on GEHC

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 5, 202611d ago 8-K Neutral 3/10 Entry $83.75 to $81.84 Now $82.96 −0.94% ▼ −2.28% −5.57% vs SPY
  2. Nov 4, 202612d ago 144 Neutral 2/10 Entry $83.75 to $81.84 Now $82.96 −0.94% ▼ −2.28% −5.57% vs SPY
  3. Oct 28, 202619d ago 8-K Bullish 6/10 Entry $75.82 to $85.81 Now $82.96 +9.42% ▲ +13.18% +13.89% vs SPY
  4. Oct 19, 202628d ago Institutional Cluster Bullish 4/10 Entry $69.72 to $71.60 Now $82.96 +18.99% ▲ +2.70% +2.84% vs SPY
  5. Sep 22, 20267w ago 8-K Neutral 2/10 Entry $66.09 to $65.37 Now $82.96 +25.53% ▼ −1.09% −0.41% vs SPY
  6. Sep 16, 20268w ago 3 Neutral 2/10 Entry $64.45 to $66.38 Now $82.96 +28.73% ▲ +3.00% +2.40% vs SPY
  7. Jul 29, 202615w ago 8-K Neutral 2/10 Entry $71.90 to $70.24 Now $82.96 +15.38% ▼ −2.31% −7.84% vs SPY
  8. May 13, 202626w ago Insider Cluster Neutral 2/10 Entry $64.26 to $62.86 Now $82.96 +29.10% ▼ −2.18% −3.98% vs SPY
  9. May 11, 202627w ago 8-K Neutral 2/10 Entry $62.29 to $61.51 Now $82.96 +33.18% ▼ −1.25% −1.33% vs SPY
  10. Apr 30, 202628w ago Insider Cluster Neutral 4/10 Entry $60.96 to $63.40 Now $82.96 +36.09% ▲ +4.00% +1.64% vs SPY
Showing 10 of 13

US Market Status

Market Closed · Opens in 7h 15m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 29, 2026